德納維製藥 DVAX 深 滬
已收盤 02-06 16:00:00 美东时间
15.50
+0.010
+0.06%
華盛通- 最 高15.50
- 今 開15.49
- 成交量 200.95万股
- 最 低 15.49
- 昨 收 15.49
- 總市值 17.62亿
- 52周最高 15.73
- 市盈率 靜 75.68
- 換手率 1.77%
- 52周最低 9.20
- 委 比 0.36%
- 總股本 1.14亿
- 歷史最高 32.49
- 量 比 0.72
- 振 幅 0.06%
- 歷史最低 0.98
- 每 手 1
- 風險率 1.88%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Sanofi targets high single digit sales growth in 2026, plans share buyback
Sanofi targets high single digit sales growth in 2026, plans share buyback LONDON, Jan 29 (Reuters) - French drugmaker Sanofi SASY.PA said on Thursday it expects sales to grow by a high-single-digit percentage in 2026, banking on strong demand for its blockbuster asthma drug Dupixent and some newer
01-29 14:30
Catalyst Watch: Big bank earnings, major healthcare + retail conferences, Fedspeak flurry, CPI
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. Monday - January 1...
01-10 04:00
Dynavax, Inhibikase and More: Stocks Trending by Analysts
Analysts are intrested in these 5 stocks: ( ($DVAX) ) and ( ($IKT) ). Here is a...
2025-12-27 17:02
美股周涨跌榜 | 奥麦罗制药周涨近64%！关键药物获FDA批准；矿业股HYMC周涨逾52%
奥麦罗制药周涨近64%！关键药物获FDA批准；矿业股HYMC周涨逾52%，此前宣布高品位银钻探结果；德纳维制药周涨近42%，获制药巨头赛诺菲安万特收购>>
2025-12-27 09:57
美股机会日报 | 26年延续涨势？美股获华尔街齐声唱多；金银价格齐创新高，矿业股盘前普涨
26年延续涨势？美股获华尔街齐声唱多，AI与降息共振下有望四年连涨；贵金属持续狂飙！金银价格齐创新高，矿业股盘前普涨；存储概念再上扬，闪迪、美光盘前涨约2%>>
2025-12-26 23:56
美股牛股 | 奥麦罗制药涨超75%，YARTEMLEA药物获得FDA批准；德纳维制药涨超38%
奥麦罗制药涨超75%，YARTEMLEA药物获得FDA批准；德纳维制药涨超38%，获法国制药巨头22亿美元收购；Sidus Space涨超33%，获美国导弹防御局合同>>
2025-12-26 18:41
William Blair Downgrades Dynavax Technologies to Market Perform
William Blair analyst Matt Phipps downgrades Dynavax Technologies (NASDAQ:DVAX) from Outperform to Market Perform.
2025-12-25 02:00
Dynavax Technologies, Omeros, Agios Pharmaceuticals, Nike And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were higher, with the Dow Jones index gaining around 200 points on ...
2025-12-25 00:06
赛诺菲以22亿美元收购Dynavax 强化疫苗业务布局
①法国制药巨头赛诺菲以约22亿美元现金收购美国疫苗公司Dynavax Technologies，以降低对哮喘药物Dupixent的依赖，实现业务多元化； ②交易将使赛诺菲获得一款已获批的乙型肝炎疫苗和一款处于早期临床试验阶段的实验性带状疱疹疫苗，预计将于2026年第一季度完成。
2025-12-24 23:59
赛诺菲以22亿美元收购Dynavax 强化疫苗业务布局
财联社12月24日讯（编辑 牛占林）法国制药巨头赛诺菲周三宣布，将以约22亿美元(19亿欧元)现金收购美国疫苗公司Dynavax Technologies。这笔...
2025-12-24 23:59
